凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
上海医药(601607)公告正文

上海市医药股份有限公司2006年第一季度报告

公告日期 2006-04-29
股票简称:上海医药 股票代码:601607

               上海市医药股份有限公司2006年第一季度报告

  1重要提示
  1.1本公司董事会及其董事保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
  1.2公司董事徐国雄先生、独立董事王巍先生因出差未出席会议,分别委托董事董平先生、独立董事李志强先生代为表决。
  1.3公司第一季度财务报告未经审计。
  1.4公司董事长钱琎先生、总经理兼总会计师余金琦女士、财务总部部长许薇薇女士声明:保证本季
  度报告中财务报告的真实、完整。
  2公司基本情况简介
  2.1公司基本信息
  股票简称                                      上海医药
  股票代码                                        600849
  董事会秘书
  姓名                                         曹伟荣
  联系地址                     上海市延安西路1566号龙峰大厦26楼
  电话                                     021-52588888
  传真                                     021-52586299
  电子信箱                                  wrcao@sina.com
  2.2财务资料
  2.2.1主要会计数据及财务指标
  币种:人民币
  本报告期末比上
  本报告期末        上年度期末数        年度期末增减
  (%)
  总资产(元)                                                           6,927,389,107.12    6,366,483,531.38                8.81
  股东权益(不含少数股东权益)(元)                                     1,782,597,223.57    1,757,568,679.18                1.42
  每股净资产(元)                                                                   3.76                3.71                1.42
  调整后的每股净资产(元)                                                           3.59                3.54                1.43
  年初至报告期期本报告期比上年
  报告期
  末          同期增减(%)
  经营活动产生的现金流量净额(元)                                           4,018,086.91        4,018,086.91              103.24
  每股收益(元)                                                                     0.05                0.05              -20.93
  减少-0.36个百
  净资产收益率(%)                                                                  1.41                1.41
  分点
  减少-0.43个百
  扣除非经常性损益后的净资产收益率(%)                                              1.36                1.36
  分点
  项      目                                            金额(元)
  (一)处置长期股权投资、固定资产、在建工程、无形
  18,132.91
  资产、其他长期资产产生的损益
  (二)各种形式的政府补贴                                                                    17,315.31
  (四)扣除公司日常根据企业会计制度规定计提的资产
  922,661.06
  减值准备后的其他各项营业外收支净额
  合      计                                              958,109.28
  2.2.2利润表
  单位:币种:审计类型:未经审计
  上年数1-3月                              本年数1-3月
  行
  项               目
  次
  母公司                合并                母公司                合并
  一、主营业务收入                                                 1     1,461,718,781.98      3,191,506,248.82    1,684,607,974.87     3,060,288,554.66
  减:主营业务成本                                                2     1,393,869,732.92      2,956,957,164.08    1,606,678,623.13     2,860,732,535.03
  主营业务税金及附加                                           3           627,171.29          4,227,528.97        1,712,091.15         4,484,157.51
  二、主营业务利润(亏损以"-敽盘盍校?                            4        67,221,877.77        230,321,555.77       76,217,260.59       195,071,862.12
  加:其他业务利润(亏损以"-敽盘盍校?                           5           599,536.66          8,182,842.42        3,002,404.63         8,405,383.66
  减:营业费用                                                    6        34,151,643.53        114,267,843.76       27,837,989.50        83,263,800.17
  管理费用                                                     7         9,504,596.91         71,600,021.83       10,353,877.45        62,624,249.14
  财务费用                                                     8         1,731,692.62          5,680,240.56       19,608,087.93        24,288,053.64
  三、营业利润(亏损以"-"号填列)                                   10       22,433,481.37         46,956,292.04       21,419,710.34        33,301,142.83
  加:投资收益(损失以"-"号填列)                                  11       12,408,740.85          2,253,156.41        7,026,143.34         3,937,596.65
  补贴收入                                                     12          489,400.00            696,905.65                                50,674.00
  营业外收入                                                   13                                276,624.28            8,000.00         1,618,954.81
  减:营业外支出                                                  14            2,271.08          1,995,184.72            6,589.16           806,817.79
  四、利润总额(亏损总额以"-"号填列)                               15       35,329,351.14         48,187,793.66       28,447,264.52        38,101,550.50
  减:所得税                                                      16        3,483,091.55         11,388,622.55        3,265,668.18         8,176,466.66
  减:少数股东损益(合并报表填列、亏损以"-"号填列)                17                              4,952,911.52                             4,743,487.50
  加:未确认的投资损失(合并报表填列)                            18
  五、净利润(净亏损以"-"号填列)                                   20       31,846,259.59         31,846,259.59       25,181,596.34        25,181,596.34
  2.3报告期末股东总数及前十名流通股股东持股表(未完成股权分置改革)
  单位:股
  报告期末股东总数(户)                                                              60,457
  前十名流通股股东持股情况
  期末持有流通股的
  股东名称(全称)                                    种类
  数量
  中国工商银行-中银国际中国精
  2,021,792   人民币普通股
  选混合型开放式证券投资基金
  朊小来                                  1,148,752   人民币普通股
  阮海良                                    983,733   人民币普通股
  曹金和                                    946,100   人民币普通股
  陈利                                      918,000   人民币普通股
  王静                                      800,000   人民币普通股
  曾国平                                    800,000   人民币普通股
  蒋汉文                                    800,000   人民币普通股
  赵孟元                                    770,000   人民币普通股
  阮小来                                    710,000   人民币普通股
  3管理层讨论与分析
  3.1公司报告期内经营活动总体状况的简要分析
  报告期内,公司实现主营业务收入30.6亿元,实现主营业务利润19507.19万元,实现利润总额3810.16万元,实现净利润2518.16万元。
  3.1.1占主营收入或主营业务利润总额10%以上的主营行业或产品情况
  √适用□不适用
  单位:元币种:人民币审计类型:未经审计
  分行业            主营业务收入       主营业务成本      毛利率(%)
  工业                          106,929,860.00      84,002,986.12
  21.44
  商业                        3,284,884,580.49   3,108,466,746.74
  5.37
  服务业                            211,312.00
  100.00
  小计                        3,392,025,752.49   3,192,469,732.86
  5.88
  公司内各业务分部相互
  331,737,197.83      331,737,197.83           -
  抵消
  合计                        3,060,288,554.66   2,860,732,535.03
  6.52
  3.1.2公司经营的季节性或周期性特征
  □适用√不适用
  3.1.3报告期利润构成情况(主营业务利润、其他业务利润、期间费用、投资收益、补贴收入与营业外收支净额在利润总额中所占比例与前一报告期相比的重大变动及原因的说明)
  □适用√不适用
  3.1.4主营业务及其结构与前一报告期相比发生重大变化的情况及原因说明
  □适用√不适用
  3.1.5主营业务盈利能力(毛利率)与前一报告期相比发生重大变化的情况及其原因说明
  □适用√不适用
  3.2重大事项及其影响和解决方案的分析说明
  □适用√不适用
  2006年第一季度期末资金被占用情况及清欠进展情况
  √适用□不适用
  单位:万元
  大股东及其附属企业非经营性占用上
  序号                                        期初数         期末数
  市公司资金的余额
  1         中国华源生命产业有限公司        6809.7         6809.7
  2          上海英达莱置业有限公司          1000           1000
  序号                 清欠方式              清欠金额       清欠时间
  1                  现金清偿               6809.7      2006年8月
  2006年4月27日
  2
  现金清偿                1000          已还清
  3.3会计政策、会计估计、合并范围变化以及重大会计差错的情况及原因说明
  □适用√不适用
  3.4经审计且被出具"非标意见"情况下董事会和监事会出具的相关说明
  □适用√不适用
  3.5预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生大幅度变动的警示及原因说明
  □适用√不适用
  3.6公司对已披露的年度经营计划或预算的滚动调整情况
  □适用√不适用
  3.7公司原非流通股东在股权分置改革过程中做出的特殊承诺及其履行情况
  □适用√不适用
  上海市医药股份有限公司
  法定代表人:钱琎
  2006年4月29日
  4附录
  资产负债表
  2006年3月31日
  编制单位:上海市医药股份有限公司
  单位:元币种:人民币审计类型:未经审计
  年初数                                     年末数
  资      产                           行次
  母体                  合并                  母体                 合并
  流动资产:
  货币资金                                                     1            68,278,196.15        314,205,621.01        191,571,221.45       502,848,578.01
  短期投资                                                     2                                 115,897,825.32                             112,243,031.50
  应收票据                                                     3            40,661,667.30         60,915,020.94         48,638,653.05        75,308,733.66
  应收股利                                                     4                                   1,411,205.32                               1,411,205.32
  应收利息                                                     5
  应收账款                                                     6           889,507,268.03      1,698,710,915.17      1,097,766,876.73     2,049,665,493.07
  其他应收款                                                   7           861,342,423.35        552,811,718.90        759,507,061.93       500,434,180.47
  预付账款                                                     8           167,581,965.09        214,169,467.82         98,840,970.22       164,119,411.71
  应收补贴款                                                   9            21,115,297.70         21,487,630.98         11,699,277.87        12,076,054.71
  存货                                                        10           766,732,269.78      1,351,051,882.90        599,875,882.43     1,226,659,484.57
  待摊费用                                                    11                                   1,972,960.18            727,913.00         3,786,541.85
  一年内到期的长期债权投资                                    21
  其他流动资产                                                24
  流动资产合计                                           30         2,815,219,087.40      4,332,634,248.54      2,808,627,856.68     4,648,552,714.87
  长期投资:
  长期股权投资                                                31         1,540,567,679.34        962,429,096.03      1,536,749,437.07       731,318,364.40
  长期债权投资                                                32
  长期投资合计                                                33         1,540,567,679.34        962,429,096.03      1,536,749,437.07       731,318,364.40
  其中:合并价差(贷差以"-敽疟硎竞喜⒈ū硖盍?                 34                                  91,215,483.34                              94,236,337.06
  固定资产:
  固定资产原价                                                39           387,242,953.64        991,371,104.65        467,033,003.94     1,223,337,412.86
  减:累计折旧                                             40            96,847,689.83        263,235,200.39        100,354,639.96       362,646,165.22
  固定资产净值                                                41           290,395,263.81        728,135,904.26        366,678,363.98       860,691,247.64
  减:固定资产减值准备                                     42             1,133,774.25          3,539,329.88          1,133,774.25         3,539,329.88
  固定资产净额                                                43           289,261,489.56        724,596,574.38        365,544,589.73       857,151,917.76
  工程物资                                                    44
  在建工程                                                    45           221,455,125.04        254,981,112.16        291,111,683.94       330,020,134.20
  固定资产清理                                                46                                                                                628,240.66
  固定资产合计                                           50           510,716,614.60        979,577,686.54        656,656,273.67     1,187,800,292.62
  无形资产及其他资产:
  无形资产                                                    51            42,600,346.41         73,667,611.72         35,611,394.67       342,335,025.91
  长期待摊费用                                                52             3,715,853.97         18,174,888.55          3,067,964.25        17,382,709.32
  其他长期资产                                                53
  无形资产及其他资产合计                                    54            46,316,200.38         91,842,500.27         38,679,358.92       359,717,735.23
  递延税项:
  递延税款借项                                                55
  资产总计                                60         4,912,819,581.72      6,366,483,531.38      5,040,712,926.34     6,927,389,107.12
  流动负债:
  短期借款                                                    61         2,037,000,000.00      2,309,940,000.00      2,269,000,000.00     2,576,890,000.00
  应付票据                                                    62           281,541,094.86        307,713,412.95                             291,328,905.49
  应付账款                                                    63           575,998,967.58      1,342,860,218.88                           1,590,403,833.98
  预收账款                                                    64           105,557,669.81        133,396,755.56                              34,629,575.01
  应付工资                                                    65                                   6,262,871.13                              10,368,533.16
  应付福利费                                                  66               254,693.48         14,109,525.30                              14,533,093.33
  应付股利                                                    67                                   4,735,511.32                               4,044,503.50
  应付利息                                                    68
  应交税金                                                    69           -64,630,844.37        -58,936,527.10        -21,489,947.45       -17,434,236.72
  其他应交款                                                  70             8,584,590.08          9,137,840.85          9,570,507.51        10,002,782.29
  其他应付款                                                  71            83,271,979.83        160,646,620.79        50,170,776.75        209,039,245.58
  预提费用                                                    72             3,409,242.50          4,146,478.38          4,110,364.13         6,202,573.92
  预计负债                                                    73
  递延收益                                                    74
  一年内到期的长期负债                                        78
  其他流动负债                                                79
  流动负债合计                                             80         3,030,987,393.77      4,234,012,708.06      2,311,361,700.94     4,730,008,809.53
  长期负债:
  长期借款                                                    81           100,000,000.00        103,241,616.46        100,000,000.00       104,440,394.98
  应付债券                                                    82
  长期应付款                                                  83            17,623,857.04         23,350,143.24         17,623,857.04        32,379,375.59
  专项应付款                                                  84
  其他长期负债                                                85
  长期负债合计                                             87           117,623,857.04        126,591,759.70        117,623,857.04       136,819,770.57
  递延税款:                                                     88
  递延税款贷项                                                89
  负债合计                                90         3,148,611,250.81      4,360,604,467.76      2,428,985,557.98     4,866,828,580.10
  少数股东权益(合并报表填列)                                     91                                 248,310,384.44                             277,963,303.45
  股东权益:
  股本                                                        92           474,310,737.00        474,310,737.00        474,310,737.00       474,310,737.00
  资本公积                                                    93           678,818,701.09        678,818,701.09        678,818,701.09       678,818,701.09
  盈余公积                                                    94           234,850,377.25        326,878,455.22       234,850,377.25        326,878,455.22
  其中:法定公益金                                            95            85,145,753.94        119,427,145.68         85,145,753.94       119,427,145.68
  减:未确认的投资损失(合并报表填列)                        96                                   1,431,019.15                               1,584,071.10
  未分配利润(未弥补亏损以"-"号表示)                          97           376,227,515.57        278,991,805.02        401,409,111.91       304,173,401.36
  其中:董事会预分方案中分配的现金股利                       97-1
  外币报表折算差额(合并报表填列)                              98
  股东权益合计                                99         1,764,207,330.91      1,757,568,679.18      1,789,388,927.25     1,782,597,223.57
  负债及股东权益总计                            100         4,912,818,581.72      6,366,483,531.38      4,218,374,485.23     6,927,389,107.12
  公司法定代表人:钱琎主管会计工作负责人:余金琦会计机构负责人:张汉宏、许薇薇
  利润表
  2006年1-3月
  编制单位:上海市医药股份有限公司
  单位:元币种:人民币审计类型:未经审计
  上年数1-3月                              本年数1-3月
  行
  项               目
  次
  母公司                合并                母公司                合并
  一、主营业务收入                                                 1     1,461,718,781.98      3,191,506,248.82    1,684,607,974.87     3,060,288,554.66
  减:主营业务成本                                                2     1,393,869,732.92      2,956,957,164.08    1,606,678,623.13     2,860,732,535.03
  主营业务税金及附加                                           3           627,171.29          4,227,528.97        1,712,091.15         4,484,157.51
  二、主营业务利润(亏损以"-"号填列)                             4         67,221,877.77        230,321,555.77       76,217,260.59       195,071,862.12
  加:其他业务利润(亏损以"-"号填列)                            5            599,536.66          8,182,842.42        3,002,404.63         8,405,383.66
  减:营业费用                                                    6        34,151,643.53        114,267,843.76       27,837,989.50        83,263,800.17
  管理费用                                                     7         9,504,596.91         71,600,021.83       10,353,877.45        62,624,249.14
  财务费用                                                     8         1,731,692.62          5,680,240.56       19,608,087.93        24,288,053.64
  三、营业利润(亏损以"-"号填列)                                   10       22,433,481.37         46,956,292.04       21,419,710.34        33,301,142.83
  加:投资收益(损失以"-"号填列)                                  11       12,408,740.85          2,253,156.41        7,026,143.34         3,937,596.65
  补贴收入                                                     12          489,400.00            696,905.65                                50,674.00
  营业外收入                                                   13                                276,624.28            8,000.00         1,618,954.81
  减:营业外支出                                                  14            2,271.08          1,995,184.72            6,589.16           806,817.79
  四、利润总额(亏损总额以"-"号填列)                               15       35,329,351.14         48,187,793.66       28,447,264.52        38,101,550.50
  减:所得税                                                      16        3,483,091.55         11,388,622.55        3,265,668.18         8,176,466.66
  减:少数股东损益(合并报表填列、亏损以"-"号填列)                17                              4,952,911.52                             4,743,487.50
  加:未确认的投资损失(合并报表填列)                            18
  五、净利润(净亏损以"-"号填列)                                   20       31,846,259.59         31,846,259.59       25,181,596.34        25,181,596.34
  公司法定代表人:钱琎主管会计工作负责人:余金琦会计机构负责人:张汉宏、许薇薇
  现金流量表
  2006年1-3月
  编制单位:上海市医药股份有限公司
  单位:元币种:人民币审计类型:未经审计
  金额
  项                                         目                  行次
  母公司                合并
  一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金                                                1         1,608,294,647.12     3,350,556,765.13
  收到的税费返还                                                            2            32,727,384.76        32,786,058.76
  收到的其他与经营活动有关的现金                                            3             4,991,922.11         5,578,444.85
  经营活动现金流入小计                                                 5         1,646,013,953.99     3,388,921,268.74
  购买商品、接受劳务支付的现金                                                6         1,444,279,439.14     3,165,754,799.02
  支付给职工以及为职工支付的现金                                              7            28,970,116.01        94,383,821.56
  支付的各项税费                                                              8            66,307,201.60       101,050,198.88
  支付的其他与经营活动有关的现金                                                9           133,510,695.41        23,714,362.37
  经营活动现金流出小计                                                      10        1,673,067,452.16     3,384,903,181.83
  经营活动产生的现金流量净额                                                      11          -27,053,498.17         4,018,086.91
  二、投资活动产生的现金流量:
  收回投资所收到的现金                                                        12                                 5,000,000.00
  取得投资收益所收到的现金                                                    13            4,168,242.27         2,002,429.77
  处置固定资产、无形资产和其他长期资产而收回的现金净额                          14            5,000,000.00         5,212,955.58
  收到的其他与投资活动有关的现金                                            15                                 1,338,450.65
  投资活动现金流入小计                                                       16            9,168,242.27        13,553,836.00
  购建固定资产、无形资产和其他长期资产所支付的现金                              18           16,962,360.45        22,358,375.70
  投资所支付的现金                                                          19           45,351,501.35        46,696,507.53
  支付的其他与投资活动有关的现金                                            20
  投资活动现金流出小计                                                 22           62,313,861.80        69,054,883.23
  投资活动产生的现金流量净额                                                      25          -53,145,619.53       -55,501,047.23
  三、筹资活动产生的现金流量:
  吸收投资所收到的现金                                                          26
  其中:子公司吸收少数股东权益性投资所收到的现金                                27
  借款所收到的现金                                                              28          232,000,000.00       272,864,278.52
  收到的其他与筹资活动有关的现金                                                29
  筹资活动现金流入小计                                                         30          232,000,000.00       272,864,278.52
  偿还债务所支付的现金                                                          31
  分配股利或利润或偿付利息所支付的现金                                          32           28,507,857.00        33,446,182.21
  其中:子公司支付少数股东的股利                                                33
  支付的其他与筹资活动有关的现金                                                34                                   361,318.99
  其中:子公司依法减资支付给少数股东的现金
  35
  筹资活动现金流出小计                                                      36           28,507,857.00        33,807,501.20
  筹资活动产生的现金流量净额                                                      40          203,492,143.00       239,056,777.32
  四、汇率变动对现金的影响                                                        41
  五、现金及现金等价物净增加额                                                    42          123,293,025.30        187,573,817.00
  1.将净利润调节为经营活动的现金流量:
  净利润(亏损以“-”号表示)
  43           25,181,596.34         25,181,596.34
  加:少数股东本期损益(亏损以“-”号表示)                                    44                                  4,743,487.50
  减:未确认的投资损失                                                         45
  加:计提的资产减值准备                                                        46
  固定资产折旧                                                              47               79,587.36          9,933,824.37
  无形资产摊销                                                              48              238,520.57          2,740,851.31
  长期待摊费用摊销                                                          49              702,269.72          2,681,486.94
  待摊费用减少(减:增加)                                                  50             -727,913.00        -1,813,581.67
  预提费用增加(减:减少)                                                  51              701,121.63          2,056,095.54
  处置固定资产、无形资产和其他长期资产的损失(减收益)                      52                3,748.87             -3,783.09
  固定资产报废损失                                                          53                                      6,021.22
  财务费用                                                                  54           27,681,014.98        34,472,419.93
  投资损失(减:收益)                                                      55           -7,026,143.34         -3,937,596.65
  递延税款贷项(减:借项)                                                  56
  存货的减少(减:增加)                                                    57          166,856,387.35        124,392,398.33
  经营性应收项目的减少(减:增加)                                          58         -238,815,628.50      -435,124,217.73
  经营性应付项目的增加(减:减少)                                          59           -1,928,060.15        238,689,084.57
  其      他                                                                60
  经营活动产生的现金流量净额                                                   65          -27,053,498.17         4,018,086.91
  2.不涉及现金收支的投资和筹资活动:
  债务转为资本                                                                 66
  一年内到期的可转换公司债券                                                   67
  融资租入固定资产                                                             68
  3.现金及现金等价物净增加情况:
  现金的期末余额                                                               69          191,571,221.45       502,848,578.01
  减:现金的期初余额                                                            70           68,278,196.15       315,274,761.01
  加:现金等价物的期末余额                                                     71
  减:现金等价物的期初余额                                                      72
  现金及现金等价物净增加额                                                     73          123,293,025.30       187,573,817.00
  公司法定代表人:钱琎主管会计工作负责人:余金琦会计机构负责人:张汉宏、许薇薇
数据加载中...
prevnext
手机查看股票